Literature DB >> 24117942

Autosomal-dominant Alzheimer's disease mutations at the same codon of amyloid precursor protein differentially alter Aβ production.

Marc Suárez-Calvet1, Olivia Belbin, Marta Pera, Nahuai Badiola, Jordi Magrané, Cristina Guardia-Laguarta, Laia Muñoz, Martí Colom-Cadena, Jordi Clarimón, Alberto Lleó.   

Abstract

Autosomal-dominant Alzheimer's disease (ADAD) is a genetic disorder caused by mutations in Amyloid Precursor Protein (APP) or Presenilin (PSEN) genes. Studying the mechanisms underlying these mutations can provide insight into the pathways that lead to AD pathology. The majority of biochemical studies on APP mutations to-date have focused on comparing mechanisms between mutations at different codons. It has been assumed that amino acid position is a major determinant of protein dysfunction and clinical phenotype. However, the differential effect of mutations at the same codon has not been sufficiently addressed. In the present study we compared the effects of the aggressive ADAD-associated APP I716F mutation with I716V and I716T on APP processing in human neuroglioma and CHO-K1 cells. All APP I716 mutations increased the ratio of Aβ42/40 and changed the product line preference of γ-secretase towards Aβ38 production. In addition, the APP I716F mutation impaired the ε-cleavage and the fourth cleavage of γ-secretase and led to abnormal APP β-CTF accumulation at the plasma membrane. Taken together, these data indicate that APP mutations at the same codon can induce diverse abnormalities in APP processing, some resembling PSEN1 mutations. These differential effects could explain the clinical differences observed among ADAD patients bearing different APP mutations at the same position. The amyloid precursor protein (APP) I716F mutation is associated with autosomal dominant Alzheimer's disease with the youngest age-at-onset for the APP locus. Here, we describe that this mutation, when compared to two other familial Alzheimer's disease mutations at the same codon (I716V and I716T), interfered distinctly with γ-secretase cleavage. While all three mutations direct γ-secretase cleavage towards the 48→38 production line, the APP I716F mutation also impaired the ε-cleavage and the fourth cleavage of γ-secretase, resembling a PSEN1 mutation. These features may contribute to the aggressiveness of this mutation.
© 2013 International Society for Neurochemistry.

Entities:  

Keywords:  APP mutations; Alzheimer's disease; amyloid-β peptide; presenilin; γ-secretase

Mesh:

Substances:

Year:  2013        PMID: 24117942     DOI: 10.1111/jnc.12466

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  15 in total

Review 1.  Amyloid beta receptors responsible for neurotoxicity and cellular defects in Alzheimer's disease.

Authors:  Tae-In Kam; Youngdae Gwon; Yong-Keun Jung
Journal:  Cell Mol Life Sci       Date:  2014-08-24       Impact factor: 9.261

Review 2.  Amyloid beta: structure, biology and structure-based therapeutic development.

Authors:  Guo-Fang Chen; Ting-Hai Xu; Yan Yan; Yu-Ren Zhou; Yi Jiang; Karsten Melcher; H Eric Xu
Journal:  Acta Pharmacol Sin       Date:  2017-07-17       Impact factor: 6.150

Review 3.  Interplay of endoplasmic reticulum stress and autophagy in neurodegenerative disorders.

Authors:  Yu Cai; Jyothi Arikkath; Lu Yang; Ming-Lei Guo; Palsamy Periyasamy; Shilpa Buch
Journal:  Autophagy       Date:  2016       Impact factor: 16.016

Review 4.  The Ubiquitin-Proteasome System and Molecular Chaperone Deregulation in Alzheimer's Disease.

Authors:  Yanuar Alan Sulistio; Klaus Heese
Journal:  Mol Neurobiol       Date:  2015-01-07       Impact factor: 5.590

Review 5.  Exploring the Involvement of the Amyloid Precursor Protein A673T Mutation against Amyloid Pathology and Alzheimer's Disease in Relation to Therapeutic Editing Tools.

Authors:  Gabriela Dumitrita Stanciu; Daniela Carmen Ababei; Razvan Nicolae Rusu; Veronica Bild; Bogdan-Ionel Tamba
Journal:  Pharmaceutics       Date:  2022-06-15       Impact factor: 6.525

Review 6.  Understanding the roles of mutations in the amyloid precursor protein in Alzheimer disease.

Authors:  S Hunter; C Brayne
Journal:  Mol Psychiatry       Date:  2017-11-07       Impact factor: 15.992

7.  Neuropathology of Autosomal Dominant Alzheimer Disease in the National Alzheimer Coordinating Center Database.

Authors:  John M Ringman; Sarah Monsell; Denise W Ng; Yan Zhou; Andy Nguyen; Giovanni Coppola; Victoria Van Berlo; Mario F Mendez; Spencer Tung; Sandra Weintraub; Marek-Marsel Mesulam; Eileen H Bigio; Darren R Gitelman; Amanda O Fisher-Hubbard; Roger L Albin; Harry V Vinters
Journal:  J Neuropathol Exp Neurol       Date:  2016-02-17       Impact factor: 3.685

Review 8.  Genetic heterogeneity in Alzheimer disease and implications for treatment strategies.

Authors:  John M Ringman; Alison Goate; Colin L Masters; Nigel J Cairns; Adrian Danek; Neill Graff-Radford; Bernardino Ghetti; John C Morris
Journal:  Curr Neurol Neurosci Rep       Date:  2014-11       Impact factor: 5.081

9.  Quantitative analysis of co-oligomer formation by amyloid-beta peptide isoforms.

Authors:  Marija Iljina; Gonzalo A Garcia; Alexander J Dear; Jennie Flint; Priyanka Narayan; Thomas C T Michaels; Christopher M Dobson; Daan Frenkel; Tuomas P J Knowles; David Klenerman
Journal:  Sci Rep       Date:  2016-06-27       Impact factor: 4.379

10.  Deposition of C-terminally truncated Aβ species Aβ37 and Aβ39 in Alzheimer's disease and transgenic mouse models.

Authors:  Jochim Reinert; Bernhard C Richard; Hans W Klafki; Beate Friedrich; Thomas A Bayer; Jens Wiltfang; Gabor G Kovacs; Martin Ingelsson; Lars Lannfelt; Anders Paetau; Jonas Bergquist; Oliver Wirths
Journal:  Acta Neuropathol Commun       Date:  2016-03-08       Impact factor: 7.801

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.